Across
- 2. Eraxis is an A-I level recommendation by _______ as initial targeted treatment of candidaemia and invasive candidiasis in non-neutropenic adult patients Vfend is indicated for the treatment of __________ aspergillosis.
- 4. What is the active ingredient of Eraxis?
- 6. There is no _____ adjustment required for Eraxis in renal and hepatic dysfunction patients.
- 7. Vfend exhibits _____ oral bioavailability and shows excellent penetration to critical tissues
Down
- 1. What is the active ingredient of Vfend?
- 3. Which pharmaceutical company markets Eraxis and Vfend?
- 5. Eraxis has no known clinically relevant drug _____________?
